Endeavor BioMedicines is developing ENV-101, a Hedgehog signaling pathway inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF), aiming to improve lung function and reverse key measures of lung fibrosis. The company also offers ENV-501, an HER3-targeted antibody-drug conjugate designed to treat HER3-positive solid tumors, addressing critical needs in oncology.
Funding
$295.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AFounders
Product
Problem
Idiopathic pulmonary fibrosis (IPF) lacks effective disease-modifying therapies that can reverse lung damage. HER3-positive solid tumors also present a significant challenge in oncology due to limited targeted treatment options.
Solution
Endeavor BioMedicines is developing targeted therapies to address unmet needs in fibrotic lung disease and oncology. Their lead candidate, ENV-101, is a Hedgehog signaling pathway inhibitor being investigated for its potential to improve lung function and reverse key measures of lung fibrosis in IPF patients. The company is also developing ENV-501, an HER3-targeted antibody-drug conjugate (ADC) designed to treat HER3-positive solid tumors by selectively delivering a cytotoxic payload to cancer cells expressing the HER3 receptor. These investigational therapies aim to disrupt the underlying causes of disease and offer transformational clinical benefits.
Target Audience
The primary target audience includes patients with idiopathic pulmonary fibrosis (IPF) and individuals with HER3-positive solid tumors, as well as the physicians who treat these conditions.
Features
- ENV-101: A small molecule inhibitor of the Hedgehog signaling pathway, a key regulator of fibrosis.
- ENV-101: Demonstrated statistically significant improvements in lung function and total lung capacity in Phase 2a clinical trials.
- ENV-501: An antibody-drug conjugate (ADC) targeting the HER3 receptor, which is overexpressed in various solid tumors.
- ENV-501: Designed with a next-generation anti-HER3 antibody for enhanced tumor cell binding and internalization.
- Clinical-stage pipeline with ongoing Phase 2b trial (WHISTLE-PF) evaluating ENV-101 for IPF.